New hope for Tough-to-Treat ovarian cancer: first human trial begins

NCT ID NCT07278336

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This is the first human study testing an experimental drug called ABBV-901 for advanced ovarian cancer that has stopped responding to standard platinum-based chemotherapy. Researchers will enroll about 207 people to test the safety, side effects, and early signs of effectiveness of ABBV-901, both by itself and combined with an existing drug called bevacizumab. The study will last about 3 years and involves frequent hospital visits for monitoring.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hadassah Medical Center-Hebrew University /ID# 278420
RECRUITING

Jerusalem, 91120, Israel
NEXT Oncology - San Antonio /ID# 278606
RECRUITING

San Antonio, Texas, 78229, United States
Next Virginia /ID# 278607
RECRUITING

Fairfax, Virginia, 22031, United States
Rambam Health Care Campus /ID# 278418
RECRUITING

Haifa, 3109601, Israel
Saitama Medical University International Medical Center /ID# 278437
RECRUITING

Hidaka, Saitama, 350-1298, Japan
Shizuoka Cancer Center /ID# 278538
RECRUITING

Sunto-gun, Shizuoka, 411-8777, Japan
Start Mountain Region /ID# 278609
RECRUITING

West Valley City, Utah, 84119, United States
The Chaim Sheba Medical Center /ID# 278416
RECRUITING

Ramat Gan, Tel Aviv, 5265601, Israel

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER